A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic ...
Pirfenidone (PFD) is an anti-fibrotic known for its use in idiopathic pulmonary fibrosis (IPF). In addition to being an anti-fibrotic, it acts as an anti-inflammatory and antioxidant as well. There have been studies on PFD in other diseases, some clinical and others preclinical.
Pirfenidone in the treatment of idiopathic pulmonary fibrosis ...
In this article, we briefly review the pathogenesis of IPF, and the completed negative and positive trials in IPF, with particular focus on efficacy and safety of pirfenidone.
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond - PMC
Pirfenidone (PFD) slows the progression of idiopathic pulmonary fibrosis (IPF) by inhibiting the exaggerated fibrotic response and possibly through additional mechanisms, such as anti-inflammatory effects.
Pirfenidone in patients with progressive fibrotic ...
2021年3月30日 · Pirfenidone has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive fibrotic interstitial lung diseases (ILDs)) other than IPF.
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic ...
2014年5月29日 · In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients...
Pirfenidone as a Cornerstone in the Management of Fibrotic ...
2024年9月30日 · As the field of antifibrotic therapy advances, pirfenidone remains a pivotal agent with the potential to significantly impact the management of fibrotic diseases across multiple organ systems. This review aims to provide clinicians and researchers with a detailed understanding of pirfenidone’s current role and prospects in treating fibrosis.
Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World ...
2024年7月11日 · Idiopathic pulmonary fibrosis (IPF) is a rare and progressive interstitial lung disease characterized by irreversible distortion of lung architecture and subsequent loss of pulmonary function. Pirfenidone is an antifibrotic agent associated with increased progression-free survival and overall survival rates, but it carries multiple side effects.